{"description":"Adverse event data for cohort b was collected only for 6 participants, as 8 participants were enrolled but 2 did not start the protocol step","eventGroups":[{"description":"treatment: 1.3 mg/m\\^2","id":"EG000","otherNumAffected":0,"otherNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"title":"Bortezomib, Cohort a"},{"description":"treatment: 1.0 mg/m\\^2","id":"EG001","otherNumAffected":0,"otherNumAtRisk":6,"seriousNumAffected":1,"seriousNumAtRisk":6,"title":"Bortezomib, Cohort b"},{"description":"treatment: 0.7 mg/m\\^2","id":"EG002","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"title":"Bortezomib, Cohort c"}],"frequencyThreshold":"0","seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":6,"numEvents":1},{"groupId":"EG002","numAffected":0,"numAtRisk":0,"numEvents":0}],"term":"unsteady gait and mental status changes"}],"timeFrame":"The adverse event data was collected for a period of 1 year and 9 months, between 4/17/2006 to 12/26/2007"}